Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “lung cancer”
- Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance StatusActive Not Recruiting
Sponsor: ETOP IBCSG Partners Foundation
NSCLC Stage IV · KRAS P.G12C
Belgium, France, Ireland, Italy, Spain +1 more
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
United States, Argentina, Australia, Brazil, Canada +21 more
Sponsor: InduPro, Inc.
Advanced Solid Tumor · Metastatic Solid Tumor · Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma
United States
Sponsor: National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma
United States
Sponsor: Boehringer Ingelheim
Non-small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +23 more
Sponsor: AstraZeneca
Lung Neoplasms
Canada
Sponsor: University of Utah
Lung Cancer · Lung Nodule
United States
Sponsor: West China Hospital
Lung Neoplasms · Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma
China
Sponsor: AstraZeneca
Lung Cancer · Breast Cancer
Brazil, Kenya
Sponsor: A2 Biotherapeutics Inc.
Solid Tumor, Adult · Colorectal Cancer · Non Small Cell Lung Cancer · Pancreatic Cancer
United States
Sponsor: GlaxoSmithKline
Lung Cancer, Non-Small Cell
United Kingdom
- Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid TumorsActive Not Recruiting
Sponsor: Monopar Therapeutics
Solid Tumor, Adult · Bladder Cancer · Urothelial Carcinoma · Triple-negative Breast Cancer
Australia
- Data Collection of Standard Care and Evaluation of NHLBI Patients and DonorsEnrolling By Invitation
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Wide Spectrum of Diseases · Hematologic Diseases
United States
- Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLCNot Yet Recruiting
Sponsor: Stanford University
EGFR · Lung Cancer (NSCLC) · Non Small Cell Lung Cancer
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer · NSCLC
United States, Argentina, Austria, Brazil, Canada +21 more
- Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.Not Yet Recruiting
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Elderly · Breast Cancer · Lung Cancer · Prostate Cancer
France
- Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompleted
Sponsor: RAPT Therapeutics, Inc.
Advanced Cancer
United States, Australia, Hong Kong, South Korea, Taiwan +1 more
- A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)Active Not Recruiting
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Argentina, Australia, Brazil, Canada +16 more
Sponsor: Qilu Pharmaceutical Co., Ltd.
Extensive-stage Small Cell Lung Cancer
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Non-small Cell Lung Cancer · Metastatic Non-Small Cell Lung Cancer · NSCLC · KRAS G12C
United States, Australia, Canada, Denmark, Spain
Sponsor: National Cancer Institute (NCI)
Mesothelioma · Malignant Mesothelioma (MM) · Early-stage Mesothelioma · Subclinical Mesothelioma
United States
Sponsor: M.D. Anderson Cancer Center
Stage III Lung Cancer AJCC v8 · Stage III Lung Non-Small Cell Cancer AJCC v7 · Stage IIIA Lung Cancer AJCC v8 · Stage IIIA Lung Non-Small Cell Cancer AJCC v7
United States
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerActive Not Recruiting
Sponsor: Muhammad Furqan
Extensive Stage Small Cell Lung Cancer
United States
Sponsor: University of Florida
Smoking
United States
Sponsor: Qilu Hospital of Shandong University
NSCLC · Tislelizumab · Anlotinib · Nab-paclitaxel
China